Eli Lilly & Co.’s announcement that it is slashing prices for its major insulin products could make life easier for some diabetes patients while easing pressure on Big Pharma. It also casts ...

Eli Lilly, along with Sanofi and Novo Nordisk make up 90% of the US market for insulin. Lilly shares were up 1.3% at $315.30. Some analysts have suggested the company was trying to get out ahead ...

Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase 3b trial, according to data published in The New England Journal of Medicine ...

Eli Lilly and Co. said it will cut prices of its most commonly prescribed insulins up to 70% and expand a program that limits out-of-pocket monthly costs for some consumers.

Eli Lilly, Novo Nordisk and ... Congress authorized a $35-per-month cap for some seniors with Medicare coverage, but that does not help those with private insurance struggling to afford the ...

Eli Lilly will cut the price of its most commonly prescribed insulin products by 70% and expand a program that caps patient costs at $35 per month, the company said on Wednesday. "While the ...

The $5.3 billion is the largest manufacturing investment in Eli Lilly’s 150-year history, chief executive David Ricks said in a statement. Big Number $18 billion.

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

What’s more, at $753, Lilly stock fetches 35 times 12-month forward earnings, down from a July peak of 57.2 times—a far less ...

Eli Lilly said it would cap the out-of-pocket cost of insulin at $35 per month. More than 8 million people with diabetes rely on insulin, which is notoriously expensive in the U.S.

Chicago Booth Insights Crain's Forum ... Now, one of those drugs, Eli Lilly's Zepbound, ... The Onion calls out Congress in full-page New York Times ad 2: ...